Antivir

Quick links to important sections

Antivir

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antivir

Quick Facts

Property Description
Active ingredient Zidovudine (AZT)
Form Tablets, Capsules, Oral Solution, Injection Solution
Pharmacological Class Antiretroviral Agent (NRTI)
Origin Synthetic Agent (Nucleoside Analog)

What Type of Medicine is Antivir (Zidovudine)?

Antivir is a prescription-only medicine whose active substance is Zidovudine, also widely known as AZT (Azidothymidine). This chemical compound is classified as an antiretroviral agent, which is a specialized type of antiviral drug. Zidovudine is a synthetic agent developed as a nucleoside analog, placing it in the specific pharmacological class of Nucleoside Reverse Transcriptase Inhibitors (NRTIs). This classification confirms the drug's role in the long-term management of chronic viral infections, a use that has been clinically recognized and supported by extensive global treatment guidelines.


Composition and Available Forms of Antivir

The medication is fundamentally a single-ingredient product, containing only Zidovudine as the therapeutic agent. To facilitate various treatment protocols, Antivir is manufactured in several dosage forms, including traditional tablets and capsules, a liquid oral solution (often prioritized for pediatric patients), and a sterile solution for injection/infusion. The availability of both oral and intravenous preparations provides essential flexibility for administration, allowing healthcare providers to choose the appropriate route of administration based on the patient's condition.


What is the General Purpose of Antiviral Agents?

The general purpose of this type of antiretroviral agent is to help control the viral load by slowing down the multiplication process of the target virus within the body. Its core function is to interfere with the virus's ability to replicate itself. Zidovudine is recognized as an essential medicine for its general role in addressing viral burden. This confirms that the compound provides a necessary means of inhibiting the propagation of the infection, often serving as a foundational component when assembling a multi-drug therapy regimen.

Regulatory References

  1. NIH DailyMed: Zidovudine Capsules
  2. WHO Essential Medicines List: Zidovudine

What side effects are possible with Antivir?

Possible Side Effects and Safety Information

Antivir (Zidovudine) has an official safety profile that defines its expected adverse reactions and regulatory constraints. The profile is primarily characterized by the risk of Hematologic Toxicity (blood disorders) and Mitochondrial Toxicity.

Frequency-Classified Adverse Reactions

The most frequently documented side effects, classified as Very Common (occurring in ge 1/10 patients) in regulatory documents, include headache, nausea, and vomiting. Reactions classified as Common (occurring in ge 1/100 to < 1/10 patients) include anemia, neutropenia, malaise, fatigue, diarrhea, and myalgia (muscle pain).

System-Organ Classes and Serious Reactions

Adverse effects are documented across multiple systems, notably Blood and Lymphatic System Disorders (e.g., anemia, leucopenia) and Gastrointestinal Disorders. The most stringent regulatory warnings focus on serious adverse reactions, which include Severe Hematologic Toxicity and potentially fatal conditions like Lactic Acidosis and Severe Hepatomegaly with Steatosis.

Safety Considerations and Exposure Patterns

Safety is often linked to the duration of exposure. Symptomatic Myopathy (muscle disease) and Lipoatrophy (loss of body fat) are specifically associated with prolonged use. The risk of Hematologic Toxicity is known to be higher in patients with advanced HIV-1 disease. Furthermore, coadministration with certain other treatments (e.g., Ribavirin/Interferon) has been linked to the exacerbation of anemia and hepatic decompensation, a risk noted in official labeling.

Overdose and Emergency Response

Antivir Overdose and when to seek help

Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations The most common presentations include headache, nausea, vomiting, malaise, fatigue, anorexia, and myalgias. Neurological findings such as transient ocular nystagmus and ataxia have also been noted.
Physiological systems affected Regulatory information highlights effects on the Hematologic system (severe anemia, neutropenia), Metabolic system (lactic acidosis), and Hepatic system (severe hepatomegaly/steatosis).
Dose-related or exposure-related factors Accidental supratherapeutic administration has been documented, particularly in newborns.
Population-specific overdose notes In overdose cases among neonates, findings included transient metabolic acidosis and subsequent persistent neutropenia.
When immediate medical help is required Regulatory instructions mandate: Contact a healthcare practitioner, hospital emergency department, or regional Poison Control Centre immediately, even if there are no symptoms.

Overdose Classifications (High-Level)

Element Official Regulatory Statement
Severity classification The potential for severe, class-related toxicities (lactic acidosis, severe hepatomegaly) is noted in the official risk profile.
Overdose-context constraints No specific antidote is known for this compound. Management relies on general supportive measures and close observation for evidence of toxicity.

Resulting Overdose Structure

Official overdose statements: • The most common manifestations are systemic and gastrointestinal, including headache, nausea, and fatigue. • Acute exposure requires immediate medical attention and contact with emergency services, regardless of current condition. • No specific antidote is known; therefore, treatment is limited to close observation and general supportive care. • Regulatory warnings cite the risk of severe hematological toxicity and class-related metabolic complications.

Connection to the overall overdose profile: Regulatory documents define the Zidovudine overdose profile based on observed transient systemic manifestations and the established risk for severe, delayed complications. Because no specific counter-agent is available, the regulatory focus mandates immediate professional consultation and continuous observation in a clinical setting to manage potential toxicity.

Therapeutic Uses of Antivir

What Antivir Treats: Main Uses and Benefits

Antivir (Zidovudine) is a foundational component in the management of established Human Immunodeficiency Virus (HIV) infection, generally used in combination with other antiretroviral agents to help manage the viral load. The therapeutic benefit supports efforts to slow the progression toward advanced symptomatic manifestations and includes the management of viral presence within the body.

Antivir is applied in therapeutic contexts related to prophylaxis, being commonly used to assist with managing symptoms and reduce the risk of vertical transmission (mother-to-child) of HIV-1, as well as being part of Postexposure Prophylaxis (PEP) regimens. It is relevant across the spectrum of the condition, from asymptomatic individuals to those with advanced symptomatic disease, and may assist in situations involving compromised systemic balance and mitigate debilitating symptoms related to systemic imbalance, such as persistent wasting and severe fatigue.

“This use is applied in clinical settings to support the patient in reducing the risk of systemic or localized discomfort during acute, high-risk periods.”

The overall benefit contributes to easing the overall symptom load and helps improve day-to-day comfort by reducing the overall burden of the chronic condition.

Quick Fact: Therapeutic Domains Description
Symptom Clusters May assist with managing symptoms related to opportunistic infections and profound fatigue.
Prophylactic Support is considered relevant in contexts involving symptom risk management for HIV transmission in perinatal and acute exposure scenarios.
Functional Stability Helps improve day-to-day comfort by easing the symptomatic impact of the chronic condition.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Antivir (Zidovudine)

Antivir (Zidovudine) is approved for use in adults and adolescents with HIV-1 infection, typically as part of combination antiretroviral therapy. Eligibility for this medicine extends to children (aged four weeks to less than 18 years) and neonates (starting within 12 hours after birth) for prophylaxis to prevent mother-to-child HIV transmission.

Classification Population Status
Absolute Prohibition Patients with prior hypersensitivity reaction to zidovudine. Contraindicated
Hematologic Status Patients with specific, severe anemia or neutropenia (low blood counts). Contraindicated
Reproductive Status Pregnant women for vertical transmission prevention. Allowed
Lactation Status HIV-positive women who are breastfeeding. Not Recommended

Use is conditional in patients with certain pre-existing health conditions. Regulatory documents advise special caution in individuals with renal impairment or hepatic impairment, as dose management or increased monitoring is required. The medicine is also used cautiously in patients with bone marrow compromise or a history of pancreatitis. For older adults (over 65), caution is advised due to the potential for age-related decline in organ function; pharmacokinetic data for this group is limited.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Antivir (Zidovudine) is defined by pharmacokinetic changes that alter systemic exposure and pharmacodynamic risks that may augment toxicity, as detailed in government regulatory sources.


Documented Exposure-Modifying Interactions

Zidovudine's primary clearance pathway is hepatic glucuronidation. Co-administration with agents that inhibit this process can increase the systemic concentration of Zidovudine (elevated AUC).

Interaction Type Examples of Interacting Substances
Increased Exposure Probenecid, Valproic Acid, Methadone, Fluconazole
Decreased Exposure Clarithromycin, Rifampin (co-administration should be avoided)

Pharmacodynamic and Avoidance Restrictions

Official labeling specifies combinations that must be avoided or are not advised due to antagonism or increased toxicity risk:

  • Antagonistic Agents: Co-administration with other antiretroviral agents, such as Stavudine, and the antineoplastic agent Doxorubicin must be avoided based on in vitro evidence.
  • Toxicity Augmentation: Use with other bone marrow suppressive agents (e.g., Ganciclovir) or Interferon alfa may increase the risk of severe hematologic and hepatic toxicities.
  • Ribavirin co-administration is not advised due to the risk of exacerbated anemia.

In patients with severe hepatic impairment or renal impairment, accumulation of Zidovudine may occur due to decreased clearance, necessitating the use of separate preparations for potential dosage adjustments.

Mechanism of Action

How Antivir Works

Blocking the Core Viral Enzyme (Reverse Transcriptase)

The drug's mechanism initiates upon its intracellular conversion by host kinases into the active metabolite, Zidovudine Triphosphate ( ZDV-TP). This active form functions as a nucleoside analog and a competitive inhibitor, targeting the Reverse Transcriptase (RT) enzyme of the target retrovirus. By structurally mimicking the natural deoxythymidine substrate, ZDV-TP readily engages the enzyme's active site.

Mechanism of DNA Chain Termination

Once incorporated into the growing viral DNA ( vDNA) strand by the RT enzyme, the Zidovudine molecule terminates the chain. This is due to the absence of a 3'-hydroxyl group, which is chemically essential for the addition of the next base. This resulting DNA chain termination immediately blocks the critical step of converting the viral RNA genome into proviral DNA, thereby preventing the retrovirus from integrating its genetic material into the host cell's genome.

Resulting Modulation of Viral Burden

By ensuring the structural failure of the viral genome, the drug suppresses the creation of new viral genetic material and halts the subsequent production of infectious virus particles. This mechanism modulates the overall viral replication cascade. The physiological consequence of this targeted enzyme inhibition is a reduction in the systemic concentration of the active virus (the viral burden).

Dosage and Administration Information

Antivir (Zidovudine) is administered as part of an antiretroviral combination regimen. The medicine is available for Oral administration (tablets, capsules, and solution) or as an Intravenous (IV) Infusion for short-term use, such as during labor and delivery, or when the oral route is not possible. The Intramuscular (IM) route is forbidden.

Standard Dosing and Timing

For most adults, the recommended total oral daily dosage is 600 mg, divided and taken in two or three administrations (e.g., 300 mg twice daily). The medicine may be taken without regard to food. For short-term IV treatment, the recommended schedule is 1 mg/kg infused over 1 hour, administered every four hours. The IV solution must be properly diluted prior to use, and rapid injection or bolus is forbidden.

Dosage Adjustments and Special Use

Population Official Dosing Rule
Severe Renal Impairment Recommended oral dosage is reduced to 100 mg every 6 to 8 hours.
Pediatric Patients Dosage is calculated based on body weight (mg/kg) or Body Surface Area (BSA) and must not exceed the adult daily dose.
Dose Interruption/Modification Single-agent formulations must be used for precise dose adjustments (e.g., due to renal changes), as fixed-dose combination products cannot be modified.

If an oral dose is missed, it should not be doubled; the next dose should be taken at its regularly scheduled time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Antivir (Zidovudine)


Overview of Research for HIV-1 Infection Treatment

The foundational research for Antivir (Zidovudine) involved Randomized Controlled Trials (RCTs) initially exploring its use as a single treatment (monotherapy). These early studies documented patterns of change in CD4+ cell counts and HIV RNA viral load measurements during the study period. Findings reported that initial virological responses observed with monotherapy were not consistently maintained over time. Later research and systematic reviews focused on Zidovudine as a key component of multi-drug regimens (cART). The combination approach was observed in studies to have more consistent patterns of change in the measured biomarkers.

Research on Preventing Vertical Transmission

The evidence for Zidovudine in relation to the risk of mother-to-child HIV transmission is based on a pivotal RCT that studied a specific three-part regimen in pregnant women and newborns. The pivotal trial reported an observed measurement pattern in the rate of confirmed HIV infection between the groups studied. Subsequent observational studies described patterns in the measured outcomes when Zidovudine was used in clinical protocols. Current standards, however, primarily utilize Zidovudine as part of modern, highly active combination regimens, limiting the contemporary relevance of the monotherapy data in this setting.

Evidence Related to Post-Exposure Prophylaxis (PEP)

Zidovudine was evaluated for its role in regimens used for Post-Exposure Prophylaxis (PEP) following acute, high-risk exposure. Due to the nature of this use, evidence relies heavily on observational studies and mathematical modeling, rather than large-scale RCTs. Research explored seroconversion measurements in individuals who completed multi-drug prophylactic regimens that included Zidovudine compared to those who did not. Because standard regimens have evolved, the data remain limited regarding the specific contribution of Zidovudine alone within modern, three-drug PEP protocols.

Frequently Asked Questions (FAQ)

Common questions about Antivir (FAQ)


Q: How long has Antivir been available for use?

Official regulatory overviews indicate that the active substance, Zidovudine, has been commercially available for its approved use since the mid-1980s. This confirms its long history within viral management protocols.


Q: Does Antivir need to be taken long-term?

Antivir is designed for the long-term management of a chronic viral infection, and official patient information indicates that its use is typically recommended to be continuous. It is intended to be taken regularly as directed by a healthcare provider, even if a person feels well, to maintain control over the viral load.


Q: What is the difference between a mild and a serious side effect of Antivir?

Official regulatory labeling classifies side effects based on severity and frequency. Serious adverse reactions include those associated with boxed warnings, such as severe blood disorders or Lactic Acidosis. In contrast, common reactions like headache and nausea are those most frequently reported and are not typically regarded as severe systemic warnings.


Q: Do all patients experience the same side effects when using Antivir?

No. The official product information classifies adverse reactions based on how often they were reported in clinical studies, such as 'Very Common' (in 1 out of 10 people or more) or 'Common.' This confirms that side effects are statistical and are not experienced by every patient who uses the medicine.


Q: Should Antivir be taken at a specific time of day?

Antivir is typically prescribed in divided doses to be taken throughout the day. To ensure the medicine maintains a consistent level in the bloodstream, regulatory information suggests taking each dose at the regularly scheduled time for the treatment to be effective.


Q: Are there any specific dietary restrictions or things to avoid while using Antivir?

The oral forms of Antivir may generally be taken without regard to food. However, regulatory warnings advise caution regarding alcohol consumption, particularly for patients with any pre-existing liver issues. This combination may increase the risk of liver damage (hepatotoxicity).


Q: Does Antivir cure the underlying condition or is it used to manage symptoms?

Official regulatory and patient information explicitly states that Antivir is not a cure for the viral condition it treats. Its core function is to reduce the amount of active virus in the blood (viral load), which helps to slow the progression of the disease and limit damage to the body’s immune system over time.


Q: Does Antivir work differently for different people or age groups?

Yes, the required amount of Antivir varies across populations. Official dosing rules often require specific adjustments based on factors such as a patient's body weight, age, or whether they have reduced kidney or liver function. These adjustments ensure the medicine is appropriately managed in the body.


Q: Can Antivir cause issues with sleep or insomnia?

According to official patient information, insomnia (trouble sleeping) is a common adverse reaction reported by patients using Antivir. If difficulty sleeping occurs, patients may wish to discuss this symptom with their healthcare provider.


Q: Can Antivir be taken with common over-the-counter pain relievers?

Yes, but certain common pain relievers may require caution. Acetaminophen (often found in over-the-counter pain medications) has a documented interaction with Zidovudine, the active ingredient in Antivir. Official documents indicate that this interaction may require adjustments to the medicine's schedule or increased monitoring by your healthcare provider.


Q: Does Antivir interact with alcohol consumption?

Official warnings indicate that alcohol consumption may interact with Antivir. This combination is associated with an increased risk of liver toxicity, which is a concern particularly for individuals with pre-existing liver conditions or a history of significant alcohol use.


Q: Can Antivir affect a person’s ability to drive?

According to official adverse reaction reports, some patients experience side effects like dizziness, headache, or general malaise. If you experience these or similar effects, regulatory information advises that your ability to safely drive or operate heavy machinery may be impaired.


Q: What is the difference between the capsule and tablet form of Antivir?

The various oral forms, including the tablet and capsule, contain the same active ingredient (Zidovudine) and are provided to allow for flexible administration. For example, some forms like the oral solution are generally prioritized for pediatric use, and regulatory guidance exists for crushing solid forms if necessary.


Q: Does Antivir have a Black Box Warning from the FDA?

Yes, official regulatory labeling includes a Boxed Warning. This warning highlights the risk of several serious adverse reactions, most notably severe blood disorders (hematological toxicity), muscle disease (myopathy), Lactic Acidosis, and severe liver enlargement (hepatomegaly).


Q: Can Antivir be crushed or split?

Yes, the official product information provides instructions for patients who may be unable to swallow whole tablets. It states that the tablets may be crushed and mixed with a small amount of liquid or soft food, but the entire mixture should be taken immediately, according to the official guidance.


Q: What long-term studies have been done on Antivir?

Studies supporting Antivir's use began with foundational Randomized Controlled Trials (RCTs). Modern research continues to evaluate its role as a key component of current, long-term combination antiretroviral therapy (cART) regimens, which focus on sustained management of the viral condition.


Q: Does Antivir affect the results of any common lab tests?

Yes. Due to the risk of blood disorders, official warnings indicate that Antivir use requires frequent monitoring via blood tests. This monitoring is necessary to check for severe effects like low red blood cell counts (anemia) and low white blood cell counts (neutropenia).


Q: How does Antivir affect the immune system?

By reducing the viral load, Antivir limits the ongoing damage the virus causes to the body’s immune system. Furthermore, regulatory information notes that as the immune system starts to recover, some patients may experience an inflammatory reaction known as Immune Reconstitution Inflammatory Syndrome (IRIS).


Q: How does Antivir affect the heart?

While generally not a primary site of action, post-marketing reports indicate that some patients have rarely reported fast, irregular, or pounding heartbeats. Regulatory documents suggest this may be an associated symptom, potentially linked to other serious adverse reactions like Lactic Acidosis.


How should Antivir be stored and disposed of?

Storage and Disposal Information

Antivir (Zidovudine) must be stored under specific environmental conditions to maintain its stability, as defined in official regulatory labeling.

Storage Requirements

The medication must be kept at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F), protected from excessive heat and moisture. The container must be kept tightly closed and in its original packaging. Certain liquid forms require protection from light and must not be frozen.

Antivir must always be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Antivir product must be disposed of according to local regulations for pharmaceutical waste. The medication should not be thrown into household trash or poured down a sink or toilet (wastewater) unless specific regulatory guidance dictates otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antivir found in:

A-Z Index: